{
  "id": 3769406,
  "title": "Pharmacologic decoupling of IRBC activation from anabolic collapse redefines ribosome biogenesis inhibition as a selective tumor suppressive strategy",
  "url": "https://urgent.news/2026/08/27/pharmacologic-decoupling-of-irbc-activation-from-anabolic-collapse",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-27T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.08.24.744089v1?rss=1"
  },
  "original_language": "en",
  "account": "Ribosome biogenesis (Ri-Bi) is a prime target in cancer treatment, but its inhibition is typically considered a broadly anti-anabolic approach. In colorectal cancer, initial therapies like FOLFOX partially impair Ri-Bi, triggering two separate outcomes: an early p53-dependent checkpoint called the impaired ribosome biogenesis checkpoint (IRBC), and a later global anti-anabolic collapse linked to toxicity and reduced effectiveness. At effective doses, these reactions have been viewed as inseparable at a pharmacological level. However, recent research illustrates that Ri-Bi inhibition can be separated and targeted specifically to the checkpoint pathway. Using a Venus-RPL11 reporter and TP53 isogenic colorectal cancer models, scientists reveal that using sub-effective doses of different Ri-Bi inhibitors alters the cellular reaction to favor IRBC-mediated p53 activation, while reducing p53-independent cell death. This adjusted dose pattern leads to significant growth reduction in TP53-proficient cells and halts the adaptation and progression of cancer during long-term treatment. Significantly, pharmacological restoration of mutant p53 (R175H) with arsenic trioxide reactivates IRBC responsiveness, extending this strategy to more advanced forms of the disease. In summary, these discoveries demonstrate that targeting ribosome biogenesis can be selectively directed towards nucleolar surveillance, thereby shifting Ri-Bi treatment towards a checkpoint-based therapeutic approach.",
  "summary": "Ribosome biogenesis (Ri-Bi) is widely targeted in cancer therapy, yet its inhibition is generally viewed as a broadly anti-anabolic intervention. In colorectal cancer, frontline treatments such as FOLFOX partly disrupt Ri-Bi, eliciting two biologically distinct outputs: an early p53-dependent checkpoint activation, known as the impaired ribosome biogenesis checkpoint (IRBC), and a later global…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}